Adding the chemotherapy drug docetaxel (docetaxel) to standard hormonal therapy for metastatic and nemetstaticescoy prostate cancer has a threefold advantage, since it improves the overall quality of life of patients, reduces the need for subsequent therapy and is cost effective. The results of large scale clinical study was presented at the Symposium on cancer of the genitourinary system (GUSC 2018), held February 8-10 in San Francisco.
Previously, according to the study of STAMPEDE, published in the journal The Lancet, have established that docetaxel is an effective treatment option for metastatic prostate cancer. The results showed the 10-month overall survival when adding a drug to androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer, compared with using only ADT.
However, the use of docetaxel in nemetstaticescoy disease was considered controversial, because of the difference in survival rates was not expressed at an early stage as well as metastatic cancer, and did not reach statistical significance, reported Medscape Medical News.
Now STAMPEDE’s lead author Professor of clinical Oncology at Birmingham University in the UK doctor Nicholas James (Nicholas D. J ames) defends this idea. “The results show that the use of docetaxel in separate nemetstaticescoy patients should be taken into consideration,” he said.
The researchers reported that docetaxel was estimated to increase the predicted survival on average by 0.89 years for patients with metastatic and 0.78 years for patients with nemetstaticescoy disease in comparison with patients receiving standard treatment.
A three-fold benefit (improved overall quality of life of the patient, reducing the need for subsequent therapy and economic efficiency) observed in nemetstaticescoy disease, “somewhat surprising and may cause clinicians to rethink how and when they use docetaxel for the treatment of prostate cancer,” concluded Dr. Nicholas James.
The most important news of healthcare now and in our Telegram channel @medpharm.